CTLA4 and melanoma: The efficacy of this approach was first proven in patients with advanced melanoma based on the improved overall survival (OS) of patients treated with the anti-cytotoxic T lymphocyte associated protein 4 (CTLA-4) directed monoclonal antibody ipilimumab [2, 3].